Skip to main content
SpringerLink
Log in

New and Emerging Treatments for Cystic Fibrosis

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Recently, a significant number of additional key medications have become licensed in Europe for the treatment of patients with cystic fibrosis (CF), including a number of inhaled antibiotics, such as nebulised aztreonam and dry powder versions of colistin and tobramycin for inhalation; dry powder inhaled mannitol, an agent to improve airway hydration and aid airway clearance; and ivacaftor, an oral therapy that directly acts on dysfunctional CFTR to correct the basic defect encountered in CF patients with the G551D CF gene mutation. The marked success of ivacaftor both in clinical trials and in post-licensing evaluation studies in treating patients with G551D and other gating mutations has greatly encouraged the ongoing development of similar therapies that can directly target the underlying cause of CF. Other therapies, including a number of anti-infectives, anti-inflammatories and replacement pancreatic enzymes, are currently undergoing clinical studies. This article reviews those treatments that have been recently licensed for CF and highlights some of the exciting emerging therapies presently under evaluation in clinical trials. In addition, it discusses some of the potential challenges being encountered by research and clinical teams in developing and delivering treatments for this condition.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stephenson AL, Mannik LA, Walsh S, et al. Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study. Am J Clin Nutr. 2013;97(4):872–7.

    Article  CAS  PubMed  Google Scholar 

  2. Que C, Cullinan P, Geddes D. Improving rate of decline of FEV1 in young adults with cystic fibrosis. Thorax. 2006;61(2):155–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Dodge JA, Lewis PA, Stanton M, et al. Cystic fibrosis mortality and survival in the UK: 1947–2003. Eur Respir J. 2007;29(3):522–6.

    Article  CAS  PubMed  Google Scholar 

  4. Jones AM, Helm JM. Emerging treatments in cystic fibrosis. Drugs. 2009;69(14):1903–10.

    Article  CAS  PubMed  Google Scholar 

  5. Riordan JR, Rommens JM, B-s Kerem, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066–73.

    Article  CAS  PubMed  Google Scholar 

  6. Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev. 2002;54(11):1373–93.

    Article  CAS  PubMed  Google Scholar 

  7. Yang Y, Li Q, Ertl H, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 1995;69(4):2004–15.

    CAS  PubMed Central  PubMed  Google Scholar 

  8. Alton EW, Boyd AC, Cheng SH, Cunningham S, Davies JC, Gill DR, et al. A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis. Thorax. 2013;68(11):1075–7.

    Article  PubMed  Google Scholar 

  9. Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014;2(7):539–47.

    Article  CAS  PubMed  Google Scholar 

  10. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci. 2009;106(44):18825–30.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–72.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187(11):1219–25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp- CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med. 2014;2(11):902–10.

    Article  CAS  PubMed  Google Scholar 

  14. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014;190(2):175–84.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D Jr. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation. J Cyst Fibros. 2015;14(1):84–9.

    Article  CAS  PubMed  Google Scholar 

  16. Hoare S, McEvoy S, McCarthy CJ, Kilcoyne A, Brady D, Gibney B, et al. Ivacaftor imaging response in cystic fibrosis. Am J Respir Crit Care Med. 2014;189(4):484.

    Article  PubMed  Google Scholar 

  17. Sheikh SI, Long FR, McCoy KS, Johnson T, Ryan-Wenger NA, Hayes D. Ivacaftor improves appearance of sinus disease on computerized tomography in cystic fibrosis patients with G551D mutation. Clin Otolaryngol. 2015;40(1):16–21.

    Article  CAS  PubMed  Google Scholar 

  18. Bellin MD, Laguna T, Leschyshyn J, Regelmann W, Dunitz J, Billings J, et al. Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study. Pediatr Diabetes. 2013;14(6):417–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Hayes D, Warren PS, McCoy KS, Sheikh SI. Improvement in hepatic steatosis in cystic fibrosis with ivacaftor therapy. J Pediatr Gastroenterol Nutr. 2015;60(5):578–9.

  20. Hayes D Jr, McCoy KS, Sheikh SI. Improvement of sinus disease in cystic fibrosis with ivacaftor therapy. Am J Respir Crit Care Med. 2014;190(4):468.

    Article  PubMed  Google Scholar 

  21. Grasemann H, Ratjen F, Solomon M. Aquagenic wrinkling of the palms in a patient with cystic fibrosis. N Engl J Med. 2013;369(24):2362–3.

    Article  CAS  PubMed  Google Scholar 

  22. Barry PJ, Plant BJ, Nair A, Bicknell S, Simmonds NJ, Bell NJ, et al. Effects of ivacaftor in cystic fibrosis patients carrying the G551D mutation with severe lung disease. Chest. 2014;146(1):152–8.

    Article  CAS  PubMed  Google Scholar 

  23. De Boeck K, Munck A, Walker S, Faro A, Hiatt P, Gilmartin G, et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014;13(6):674–80.

    Article  PubMed  Google Scholar 

  24. Davies JC, Roberston S, Green Y, Rosenfeld M. An open-label study of the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2 to 5 years with CF and a CFTR gating mutation: the KIWI study. Pediatr Pulmonol. 2014;49(S38):S286.

    Google Scholar 

  25. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012;142(3):718–24.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, et al. WS23.6 ivacaftor treatment in patients with cystic fibrosis who have an R117H-CFTR mutation, the KONDUCT study. J Cyst Fibros. 2014;13:S44.

    Article  Google Scholar 

  27. Moss R, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, et al. S17 Effects of ivacaftor in CF patients with R117H-CFTR. Pediatr Pulmonol. 2014;49(S38):S221.

    Google Scholar 

  28. Nick JA, Rodman D, St Clair C, Jones MC, Li H, Higgins M, et al. Effect of ivacaftor in patients with cystic fibrosis, residual CFTR function, and FEV1 ≥40 % of predicted, N-of-1 study. Pediatr Pulmonol. 2014;49(S38):S285.

    Google Scholar 

  29. Goodman N, Watson K, Charlwood J, Schuhmann I, Nicholls I, Boulton C, et al. QBW251 is a novel CFTR potentiator that has been studies in healthy volunteers. Pediatr Pulmonol. 2014;49(S38):S232–3.

    Google Scholar 

  30. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci. 2011;108(46):18843–8.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Clancy J, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012;67(1):12–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014;2(7):527–38.

    Article  CAS  PubMed  Google Scholar 

  33. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015 (Epub ahead of print).

  34. Vertex submits applications in the U.S. and europe for approval of lumacaftor in combination with ivacaftor for people with cystic fibrosis who have two copies of the F508del mutation [19/11/14]. Available from: http://investors.vrtx.com/releasedetail.cfm?releaseid=880537.

  35. Cholon DM, Quinney NL, Fulcher ML, Esther CR, Das J, Dokholyan NV, et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med. 2014;6(246):246ra96.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Veit G, Avramescu RG, Perdomo D, Phuan P-W, Bagdany M, Apaja PM, et al. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med. 2014;6(246):246ra97.

    Article  PubMed  Google Scholar 

  37. Donaldson S, Pilewski J, Griese M, Dong Q, Lee P-S. WS7. 3 VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation: interim analysis. J Cyst Fibros. 2013;12(S1):S14.

    Article  Google Scholar 

  38. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680–9.

    Article  PubMed  Google Scholar 

  39. Smyth AR, Bell SC, Bojcin S, et al. European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros. 2014;13(S1):S23–42.

    Article  PubMed  Google Scholar 

  40. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135(5):1223–32.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9):921–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Cystic Fibrosis Foundation. Patient registry annual data report 2013. Bethesda: Cystic Fibrosis Foundation; 2013.

    Google Scholar 

  43. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros. 2011;10(1):54–61.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Schuster A, Haliburn C, Doring G, Freedom Study G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax. 2013;68(4):344–50.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Clancy JP, Dupont L, Konstan MW, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax. 2013;68(9):818–25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med. 2012;185(2):171–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2011;55(6):2636–40.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Elborn JS, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, et al. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros. 2015. doi:10.1016/j.jcf.2014.12.013.

  49. Stass H, Weimann B, Nagelschmitz J, Rolinck-Werninghaus C, Staab D. tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase 1, randomized, dose-escalation study. Clin Ther. 2013;35(10):1571–81.

    Article  CAS  PubMed  Google Scholar 

  50. Milla CE, Chmiel JF, Accurso FJ, et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol. 2014;49(7):650–8.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Tullis DE, Burns JL, Retsch-Bogart GZ, Lipuma JJ, et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros. 2014;13(3):296–305.

    Article  CAS  PubMed  Google Scholar 

  52. Powell LC, Sowedan A, Khan S, et al. The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms. Biofouling. 2013;29(4):413–21.

    Article  CAS  PubMed  Google Scholar 

  53. Walshaw M, McElvaney G, Williams R, Morice A, Carroll M, Haworth C, et al. A first-in-patient clinical trial demonstrates that inhaled alginate oligosaccharide (OligoG) is well tolerated in cystic fibrosis (CF) patients. J Cyst Fibros. 2014;13(S2):S58.

    Article  Google Scholar 

  54. Lai HC, Fitzsimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW, Farrell PM. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med. 2000;342(12):851–9.

    Article  CAS  PubMed  Google Scholar 

  55. Eigen H, Rosenstein BJ, Fitzsimmons S, Schidlow DV. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation prednisone trial group. J Pediatr. 1995;126(4):515–23.

    Article  CAS  PubMed  Google Scholar 

  56. Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis. Trends and physician attitudes. Chest. 1999;115(4):1053–8.

    Article  CAS  PubMed  Google Scholar 

  57. Konstan MW, Doring G, Heltshe SL, Lands LC, Hilliard KA, Koker P, et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros. 2014;13(2):148–55.

    Article  CAS  PubMed  Google Scholar 

  58. Sagel SD. The challenges of developing effective anti-inflammatory agents in cystic fibrosis. J Cyst Fibros. 2015;14(2):164–6.

    Article  PubMed  Google Scholar 

  59. Calabrese C, Tosco A, Carnovale V, Basile C, Magliocca A, Quattrucc S, et al. Randomized, single-blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis. J Cyst Fibros. 2015;14(2):203–10.

    Article  CAS  PubMed  Google Scholar 

  60. Griese M, Kappier M, Eismann C, Ballmann M, Junge S, Rietschel E, et al. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized controlled trial. Am J Respir Crit Care Med. 2013;188(1):83–9.

    Article  CAS  PubMed  Google Scholar 

  61. Conrad C, Lymp J, Thompson V, Dunn C, Davies Z, Chatfield B, et al. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. J Cyst Fibros. 2015;14(2):219–27.

    Article  CAS  PubMed  Google Scholar 

  62. Taylor-Cousar JL, Wiley C, Felton LA, St. Clair C, Jones M, Curran-Everett D, et al. Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. J Cyst Fibros. 2015;14(2):228–36.

    Article  CAS  PubMed  Google Scholar 

  63. Fila L, Grandcourtova A, Vichova M, Valentova Bartakova L. Influence of treatment with sildenafil on lung function and exercise tolerance in cystic fibrosis adults. J Cyst Fibros. 2013;12(S1):S67.

    Article  Google Scholar 

  64. Noel S, Dhooghe B, Leal T. PDE5 inhibitors as potential tools in the treatment of cystic fibrosis. Front Pharmacol. 2012;3:167.

    CAS  PubMed Central  PubMed  Google Scholar 

  65. Carlile GW, Robert R, Goepp J, Matthes E, Liao J, Kus B, et al. Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking. J Cyst Fibros. 2015;14(1):16–25.

    Article  CAS  PubMed  Google Scholar 

  66. Donaldson SH, Taylor-Cousar JL, Rosenbluth D, Zeitlin P, Chmiel J, Jain M, et al. Safety, tolerability, and pharmacokinetics of the intravenous S-nitrosoglutathione reductase inhibitor N6022: an ascending-dose study in subjects homozygous for the F508Del-CFTR Mutation. Pediatr Pulmonol. 2014;49(S38):S308.

    Google Scholar 

  67. Shoemaker S, Madagere A, Troha J, Abbas V, Galloway C, Elhard M. Safety, tolerability, and pharmacokinetics of the oral S-nitrosoglutathione reductase inhibitor N91115: a multiple ascending-dose study in healthy subjects. Pediatr Pulmonol. 2014;49(S38):S313–4.

    Google Scholar 

  68. Callahan KA, Diener-West M, Schoeberlein C, Boyle MP, Zeitlin PL. Prelimionary safety profile of digitoxin to treat CF. Pediatr Pulmonol. 2014;49(S38):S293.

    Google Scholar 

  69. Springmann EB, Grosswald R, Philpot E, MacGregor G, Horsley A, Bilton D, et al. A phase 1 clinical trial of CTX-4430 in cystic fibrosis patients. Pediatr Pulmonol. 2014;49(S38):S311.

    Google Scholar 

  70. Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer R, et al. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros. 2013;12(3):241–8.

    Article  CAS  PubMed  Google Scholar 

  71. Rocca J, Manin S, Hulin A, Pruliere-Excabasse C, Verbecq-Morlot W, Wohlhuter-Haddad A, et al. Sulindac, a new use for an old drug in CF: CFTR potentiator and COX-independent anti-inflammatory effects. Pediatr Pulmonol. 2014;49(S38):S304.

    Google Scholar 

  72. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331(10):637–42.

    Article  CAS  PubMed  Google Scholar 

  73. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354(3):241–50.

    Article  CAS  PubMed  Google Scholar 

  74. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354(3):229–40.

    Article  CAS  PubMed  Google Scholar 

  75. Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, et al. Inhaled hypertonic saline in infants and children less than six years of age with cystic fibrosis: the ISIS randomized trial. J Am Med Assoc. 2012;307(21):2269–71.

    Article  CAS  Google Scholar 

  76. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J. 2011;38(5):1071–80.

    Article  CAS  PubMed  Google Scholar 

  77. Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012;185(6):645–52.

    Article  CAS  PubMed  Google Scholar 

  78. Deterding R, Retsch-Bogart G, Milgram L, et al. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol. 2005;39(4):339–48.

    Article  PubMed  Google Scholar 

  79. Deterding RR, Lavange LM, Engels JM, et al. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med. 2007;176(4):362–9.

    Article  CAS  PubMed  Google Scholar 

  80. Accurso FJ, Moss RB, Wilmott RW, et al. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med. 2011;183(5):627–34.

    Article  CAS  PubMed  Google Scholar 

  81. Ratjen F, Durham T, Navratil T, et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros. 2012;11(6):539–49.

    Article  CAS  PubMed  Google Scholar 

  82. Moss RB. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr. 2013;162(4):676–80.

    Article  PubMed  Google Scholar 

  83. Zeitlin PL, Boyle MP, Guggino WB, et al. A phase I trial of intranasal Moli 1901 for cystic fibrosis. Chest. 2004;125(1):143–9.

    Article  CAS  PubMed  Google Scholar 

  84. O’Riordan TG, Donn KH, Hodsman P, et al. hyperkalemia associated with inhalation of a potent ENaC antagonist: phase 1 trial of GS-9411. J Aerosol Med Pulm Drug Deliv. 2014;27(3):200–8.

    Article  PubMed  Google Scholar 

  85. Borowitz D, Stevens C, Brettman LR, et al. International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. J Cyst Fibros. 2011;10(6):443–52.

    Article  CAS  PubMed  Google Scholar 

  86. Borowitz D, Stevens C, Brettman LR, et al. Liprotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis. J Pediatr Gastroenterol Nutr. 2012;54(2):248–57.

    Article  CAS  PubMed  Google Scholar 

  87. VanDevanter DR. How will we evaluate multiple inhaled antibiotic efficacy or effectiveness? Pediatr Pulmonol. 2014;49(S38):164–5.

    Google Scholar 

  88. Barry PJ, Jones AM, Webb AK, Horsley AR. Sweat chloride is not a useful marker of clinical response to Ivacaftor. Thorax. 2014;69(6):586–7.

    Article  PubMed  Google Scholar 

  89. Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest. 2013;143(1):14–8.

    Article  CAS  PubMed  Google Scholar 

  90. Seliger VI, Rodman D, Van Goor F, Schmelz A, Mueller P. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation. J Cyst Fibros. 2013;12(6):706–13.

    Article  CAS  PubMed  Google Scholar 

  91. Konstan MW, Plant BJ, Elborn JS, Rodriguez S, Munck A, Ahrens R, et al. Efficacy response in CF patients treated with ivacaftor: post-hoc analysis. Pediatr Pulmonol. 2015;50(5):447–55.

  92. Sawicki GS, Ren CL, Konstan MW, Millar SJ, Pasta DJ, Quittner AL, et al. Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. J Cyst Fibros. 2013;12(5):461–7.

    Article  PubMed Central  PubMed  Google Scholar 

  93. Sawicki GS, Tiddens H. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol. 2012;47(6):523–33.

    Article  PubMed  Google Scholar 

  94. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009;8(2):91–6.

    Article  PubMed Central  PubMed  Google Scholar 

  95. Quittner AL, Zhang J, Marynchenko M, Chopra PA, Signorovitch J, Yushkina Y, et al. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest. 2014;146(1):142–51.

    Article  PubMed  Google Scholar 

  96. Siracusa C, Clancy JP, Drotar D. Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor. Pediatr Pulmonol. 2014;49(S38):440.

    Google Scholar 

  97. Modi AC, Lim CS, Yu N, Geller D, Wagner MH, Quittner AL. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros. 2006;5(3):177–85.

    Article  PubMed  Google Scholar 

  98. Nick JA, Moskowitz SM, Chmiel JF, Forssen AV, Kim SH, Saavedra MT, et al. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc. 2014;11(3):342–50.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  99. Bush A, Simmonds NJ. Hot off the breath: ‘I’ve a cost for’—the 64 million dollar question. Thorax. 2012;67(5):382–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Manchester Adult Cystic Fibrosis Centre, University Hospitals South Manchester NHS Trust, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK

    Peter J. Barry & Andrew M. Jones

Authors
  1. Peter J. Barry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew M. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew M. Jones.

Ethics declarations

Funding

No funding was sought or received to support the writing of this manuscript.

Conflicts of interest

Dr. AM Jones has received consultancy fees from Gilead and Vertex Pharmaceuticals, and support for educational meetings from Forrest. Dr. P Barry has received consultancy fees from Vertex Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barry, P.J., Jones, A.M. New and Emerging Treatments for Cystic Fibrosis. Drugs 75, 1165–1175 (2015). https://doi.org/10.1007/s40265-015-0424-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0424-8

Keywords

Search

Navigation